Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accumulated Expenses: 2021-2025

Historic Accumulated Expenses for InMed Pharmaceuticals (INM) over the last 3 years, with Sep 2025 value amounting to $274,250.

  • InMed Pharmaceuticals' Accumulated Expenses rose 15.03% to $274,250 in Q3 2025 from the same period last year, while for Sep 2025 it was $274,250, marking a year-over-year increase of 15.03%. This contributed to the annual value of $490,405 for FY2025, which is 0.44% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Accumulated Expenses of $274,250 as of Q3 2025, which was down 44.08% from $490,405 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Accumulated Expenses peaked at $839,638 during Q2 2022, and registered a low of $101,775 during Q4 2023.
  • Over the past 3 years, InMed Pharmaceuticals' median Accumulated Expenses value was $345,350 (recorded in 2024), while the average stood at $357,748.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Accumulated Expenses plummeted by 35.41% in 2023, and later surged by 231.35% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $382,114 in 2021, then reached $839,638 in 2022, then tumbled by 35.41% to $101,775 in 2023, then soared by 231.35% to $337,236 in 2024, then climbed by 15.03% to $274,250 in 2025.
  • Its Accumulated Expenses stands at $274,250 for Q3 2025, versus $490,405 for Q2 2025 and $464,665 for Q1 2025.